Product Description

DOXLINE 100 is a sterile injectable formulation of Doxycycline 100 mg, developed for the effective management of moderate to severe bacterial infections. It is particularly useful in hospitalized patients or in situations where oral therapy is not feasible, ensuring rapid and reliable systemic action. Doxycycline exerts its antibacterial effect by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, thereby preventing the addition of amino acids to the growing peptide chain. This bacteriostatic action helps control the growth and spread of susceptible microorganisms.

DOXLINE 100 offers broad-spectrum antibacterial activity and is indicated in respiratory tract infections, urinary tract infections, skin and soft tissue infections, rickettsial infections, and septicemia or other serious systemic infections, making it a valuable option in acute and critical care settings.

Indications:

• • Severe bacterial infections where oral therapy is not feasible
  • Respiratory tract infections (e.g., pneumonia, bronchitis)
  • Urinary tract infections
  • Skin and soft tissue infections
  • Rickettsial infections (e.g., typhus, Rocky Mountain spotted fever)
  • Septicemia and serious systemic infections

Therapeutic Segment Positioning:

Antibiotics